Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Cristina Puig-Saus(APLA Health), Alena Gros(Unknown), Justin D. Saco(University of California, Los Angeles), Michael C Yi, John P. Greer(Vanderbilt University Medical Center), Michael T. Bethune, Andrew Conroy, Gabriel Abril-Rodríguez(University of California, Los Angeles), Olivier Dalmas, Melissa J Pilling, Kyle Jacoby, Sara Said, Barbara Sennino, Clifford L. Wang(Stanford University), Robert Moot, Huiming Xia(James S. McDonnell Foundation), Boi Quach, Salemiz Sandoval, Agustin Vega-Crespo(University of California, Los Angeles), Xiaoyan Bao(Broad Institute), Phillip Peabody, Bartosz Chmielowski(UCLA Health), Diana Nguyen, Jonathan Hoover(Genomic Health (United States)), Marc Ting, Deborah Jean Lee Wong(University of California, Los Angeles), Ramya Tunuguntla(Stanford University), Shahab Chizari(University of Pennsylvania), Songming Peng, Jasreet Hundal(James S. McDonnell Foundation), Benjamin Yuen, Egmidio Medina(University of California, Los Angeles), Christine Shieh(Thomas Jefferson University), Zheng Pan(Nankai University), Susan P. Foy(Sunesis (United States)), Theresa Hunter(Unknown), Saparya Nayak, Sidi Zhao(James S. McDonnell Foundation), Grace Cherry(University of California, Los Angeles), Katharine Heeringa, Duo An, Daniel E. Speiser(University of Lausanne), Bhamini Purandare, Ignacio Baselga-Carretero(University of California, Los Angeles), Ivan Perez-Garcilazo(University of California, Los Angeles), Yan Ma, Kevin Shao, Sameeha Jilani(University of California, Los Angeles), William Lu, Claire McHugh
Cited by 206
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
|Journal of Clinical Investigation|2014|1.1k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
|JAMA|2016|1.1k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k